Ascendis Pharma AS News - ASND | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Ascendis Pharma AS (ASND)
Ascendis Pharma AS (ASND) News

Ascendis Pharma AS (ASND)

138.58

-1.73

( -1.23% )

Updated: 02:38:39

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

1
Next

Monksdream

Monksdream 10 months ago

ASND new 52=week high

Monksdream

Monksdream 10 months ago

ASND new 52 week high

MiamiGent

MiamiGent 10 months ago

What goes down, must go up :)
Hope you banked, monk.

Monksdream

Monksdream 10 months ago

ASND new 52 week high

Monksdream

Monksdream 12 months ago

ASND new 52 week high

MiamiGent

MiamiGent 2 years ago

ASND 161 shares traded in pre-mkt. Take your profits- nobody going to hold up this dilution candidate.
Bearish

MiamiGent

MiamiGent 2 years ago

ASND After just one day of wooing, ASND is FALLING ...........in love with my short.
Irresistible attraction: fourteen-month delay on average, need for more money and a red market with housing assuring further rate increase.
Quote as of 5/02/2023 2:44PM ET
$86.375 -$0.365 (-0.421%)
Bearish
https://www.bing.com/videos/search?q=you+tube+music+roy+orbison+i%27m+falling&view=detail&mid=17436B40AE02F042D00317436B40AE02F042D003&FORM=VIRE

MiamiGent

MiamiGent 2 years ago

$ASND
A complete response letter (CRL) from the FDA delays a product’s entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them.
FDA NEWS
Bearish

MiamiGent

MiamiGent 2 years ago

ASND Net Income -$622,419,000 in 2022

Anyone want to venture a guess when the raise will come?

I'll take a WAG and say within two weeks.

MiamiGent

MiamiGent 2 years ago

ASND Quote as of 5/02/2023 10:14AM ET

$88.07 +$1.33 (+1.533%)

I'm down -3.22% on my short. Did not choose well- 100% owned by institutions.. not easily budged.
I am counting on red days, 3 day rule, CRL and outside chance of a raise- it's all I got, lol

https://stockcharts.com/h-sc/ui?s=ASND

MiamiGent

MiamiGent 2 years ago

Short today at 85.34

How long will this languish before possible good news?

Will need to raise more $$

crudeoil24

crudeoil24 3 years ago

Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric Growth Hormone Deficiency > ASND
3:46 pm ET August 25, 2021

By Stephen Nakrosis

Ascendis Pharma A/S on Wednesday said the U.S. Food and Drug Administration approved its Skytrofa as a treatment for Pediatric Growth Hormone Deficiency.

The company said Skytrofa, or lonapegsomatropin-tcgd, is the first once-weekly treatment approved to treat Pediatric Growth Hormone Deficiency.

The company also said Skytrofa was approved to treat "pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone."

The company said the approval includes its Skytrofa Auto-Injector and cartridges, which enable families to store the medicine at room temperature for up to six months.

The company said availability of Skytrofa in the U.S. is expected soon.

Ascendis said it would hold an investor conference call at 4:30 p.m. ET today.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

crudeoil24

crudeoil24 3 years ago

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Ascendis Pharma AS

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions